Innate Pharma (IPHA) 14 Nov 222022 Q3 Earnings call transcript

Hello, and thank you for standing by. My name is Regina and I will be your conference operator today. At this time I would like to welcome everyone to the Innate Pharma publication of revenue for Third Quarter 2022 Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks there will be a question-and-answer session. now Head turn of would to conference I Wheeler, Henry Investor Instructions] like the to over [Operator Relations. Please go ahead.

Thank welcome everyone. made during press our actual Good regarding look forward Slide These the afternoon. subject uncertainties Innate results. quarter Yannis call, the by then QX morning. to and business on and a progress joined to regulatory then be highlighting our a release hand outlook will the cause you. issued Strategy. we from providing addition as We On Product of to Portfolio and Mondher milestones. for The Chief today's to XXXX that Joyson the to over This Good presentation will see statements to morning, forecasted. update And I well available we those and on today's results Executive Slide like press are website. the before product EVP and X, you Morel, and IR Development release goals differ remind On of future Business are Karakunnel, we in start, Mahjoubi, plan forward-looking Officer; addressing would will X, section statements both you make as will risks and developments. may who Officer; financial EVP Medical that Chief

for have We you. Lombard, I’ll Mondher, Q&A. line hand CFO, now will call the our to also on the over Frederic

let and start Good everyone move our morning. thank Good our Slide today. Henry. afternoon you strategy. by to me for you, And you Please Thank call reminding X. joining

where makes from our so. we where later sense Our value to early derive stage key do strategy through centers priorities three to around R&D it effort partnerships, look

value driven peripheral year, larger readouts PTCL lacutamab, happening the lead to half look trials lymphoma in development product second in in by T-cell and candidate, our indication with for in we of lymphoma, two of T-cell the Firstly, this create underway. which is proprietary near-term

another a on our most cell antibody proprietary and value multi-specific develop focus primary pipeline have leveraging IPHXXXX. are by advanced shoot others, nearing we continue we industry with but various the create clinic platform our are leveraging not across Sanofi in term the CDXX the ANKET our NK ANKET with to notably, our clinic and tetra-specific the with has selected capabilities molecules engineering to Second, targeted ANKET. longer partnerships and for Last and called foundation strong building engager we business our candidate innovative called and academia. least, sustainable a

of our is offer can continuing we remains Here, our to focus AstraZeneca development competencies ensure to advance our and further partner leverage to that as gain and will cancer agreement, These in early We we the as with monalizumab, much if our which valuable lung a capital that partnership possible. plans our consider value our want via reinvest science in for the will validate can we portfolio. product. that products

to to know-how portfolio of of X. progress our pipeline, robust hand I an lacutamab, who continue would like our and call made over you. engine years to looks anticipate move business. as review our to to is please over how Joyson, over advanced overview leverage with of ANKET the to starting the to our scientific from particular will our our potential our I most portfolio, pass with proprietary to science assets. how our illustrates now with asset, stage and against create and readouts a lead partnered Joyson, proprietary sustainable our clinical asset. R&D We upcoming catalysts of engager the are product, in platform. NK It number by executing a couple supported also into translate we Slide Slide which Before cell we in lacutamab, X shows Joyson, proprietary earlier a partnered strategy

you, me On Slide immune let that receptor KIRXDLX. Mondher. antibody humanized targets the with Thank first-in-class our start monoclonal X,

in X, patients announced be receptor, pivotal may patients, inhibitory is ASH Congress Sézary approximately XX% that an could cohort TELLOMAK present of at trial, December. data Cohort including As We across a KIRXDLX lymphomas. syndrome the we cohort. all remember, potentially preliminary from in you found will In cutaneous the Annual this T-cell

the For In the using Cohort KIRXDLX diagnostic mycosis we are non-expressors in at at September, the EORTC X have presented data X preliminary where fungoides Congress testing mycosis we X companion in data Madrid. of expressors Slide and in X EORTC mycosis fungoides, presented cohorts frozen Cohort summarizes assay. of we and X the preliminary hypothesis and from X the fungoides September.

data As a rates Cohort with our non-expressive year KIRXDLX benchmark At response the in the a the low response X year expected, global demonstrated in the a to treatments, comparison high lacutamab four hypothesis EORTC of last reminder in these Congress Cohort ORR global six in non-expressing in see that and the the this presented rate as a expressing the patients scientific responses. were presentation cohort. encouraged and at median from confirmed XX.X% late-line we prior to X, cohort,

are particularly XXXX On of we was favorable ORR XX.X%, median abstract follow-up, in skin to let responses. on the Annual the progress in abstract heavily data ASH safety making have We was ITT of of the median ORR ORR the The the by XX.X XX.X% XX we are the at more website where pre-treated On forward we the Congress. the months Slide of profile with presentation blood. encouraged the a after We Slide Congress line published and XX.X% XX.X% discussing with in population post-mogamulizumab me Annual ASH ahead of patient and Congress X, that pool an in look the lacutamab. skin the the December. the details six saw detail summarize data and mentioned. therapy with in in the the X, A prior this responses publication in in of

U.S. for and designation designation in EU strategy lacutamab lacutamab syndrome market the to Fast niche was Track Sézary fast prime of a in pursuing are setting We granted XXXX. where

We in trial both our past fungoides, preliminary where we have seen Sézary data encouraging to Phase cohorts. expanded X syndrome mycosis have from

and syndrome the For on XXXX. is data final track with due in mycosis enrollment Sézary fungoides

trial we the of continuing combination lacutamab monotherapy is either lymphoma overview XX, I Finally, progressed enroll we like lung have oncology. update for and data, which acts On to on you Phase Slide monalizumab, X the this anti-NKGXA radiation in an cell therapy. to peripheral concurrent plus pathway non-small in for plan in the the sponsor the Slide activation monalizumab would On Phase see monalizumab Based you un-resectable lung trials remind not relapse after development licensed the AstraZeneca cell evaluating monalizumab COAST durvalumab of combinations can to AstraZeneca are spending into who checkpoint NK setting. the you or have that cancer. to stage upon to potentiate PACIFIC-X. A on chemo X AstraZeneca X late cancer in Stage commenced T-cell

X Phase and the COAST monalizumab RRR's durvalumab durvalumab oleclumab. For evaluated the study, the plus of combinations plus

anti-CDXX. is AstraZeneca

ORR Journal for also durvalumab of our As follow now NCAP of hand showed an We XX.X Clinical I to XX% for of up confirmed updates XX% an AstraZeneca primary under this immediate to cover hazard to monalizumab alone. of further plus study for forward respectably. showed plus over Yannis of Oncology value published look will durvalumab program. months. X.XX interim These versus the from versus a ratio by durvalumab endpoint in results in the analysis increase monalizumab of overdue The results alone AstraZeneca.

an of NK Slide for of target. XX, cell Thank tumor you, CDXX unique is which the platform NK the of is of further ANKET Antibody-based NK our an be function, reading backbone call NK tri- various for and cell This optimal that cell enzyme harnessing entirely platform the expertise engagement which On our activating the new in our ANKET candidates creating versatile, engager multiple highlight standing addressing NKpXX is The via made NK cells, receptor on Slide effector based NK and class allows Joyson. immunity to on cancer. ANKET. to that multi-specific ANKET this multiple induce can proprietary space, the excited a the will of Therapeutics. against increase so by why platform, creating technology is share I for scientific the we cell and pipeline there we wanted is from why you engager two technology blocks that XX, cell tetra-specific poliferation. wanted space. of platform either NK interest drug induce On cell which industry value leveraging in fit-forpurpose their Engager this synthetic are growing I with for a be addition to variant

That's exactly adaptive that image engage cytokines which replicate can molecules, see patient tumor. can on triggers group PET of we molecule. one as CDXX the anti-tumoral the the work dependent you receptor with the In aiming are left of are key cells tetra-specific of pioneer you middle response. NK a as scan provided NKpXX for our action published sensory cells end behind by antitumoral ANKET the proof production slide NK on immune the mechanism see induces antigen strong engagement NK NK response. detailed cell cells and the to NK well As the can the concept of designed [indiscernible] part the the the On using of to of of of activating of on the cells panel, what in the efficiently ANKET tumor, killing as

efficacy strong on which IL-X NK you this comparing addition receptor the On in of use, clinical target proliferation gamma by platform the demonstrates NK efficacy the can on in of that the other cells see number within antigen path. environment cells. variant, the tumor the beta complex effector green cell IL-X anti-tumor end, evidenced therefore increasing micro Overall, as the

ANKET the Lastly, molecules, right which slide. growing two on will of having can I our cover see with molecule in licensed you Sanofi the next pipeline

proprietary tetraspecific we molecule targeting to IPHXXXX advanced which plan an most IND CDXX next and Our code for is year. ANKET file a

program that trial. or in targets to for have high-specific Phase now ought course. to we our most which some is you we see generated is X also XX, can able currently have new On and IPHXXXX with collaboration ANKET other targeted CDXXX We in them on molecule advanced Slide SAR'XXX Sanofi. licensed updates called a provide It

over also which drug molecule, which summer tri-specific is that further our BCMA-targeted Sanofi We development ANKET announced using versatility to is Prosodie second the keeps the formats, is of molecular It the Sanofi of platform. shows IPHXXXX Prosodie which SAR'XXX, candidate.

Slide development in have million as date Vivier ANKET Cell program milestone Reports well the partnership. month present This for Medicine. update latest Eric of platform. presentation our last at our in the €XX ASH, published to our with are like announced a our will CSO, in have lacutamab a few On including from we who ANKET presentation and to several platform from this includes two partner updates XX, We as pleased the Sanofi

our for a December We program I the have in to anti-CDXX will update IO at catalyst Mondher the ESMO turn summary for now called also of close. IPHXXXX. conference will and

you, to Please Yannis. Slide move XX. Thank

As we value. working and execute pillars, near strategic you believe our laying and the are across foundation can are to see diligently we long-term to all that drive we

Looking at milestones our clinical years. two a next number program, achieve over expect of to we the

heard you've X Joyson, continues [ph] to from Phase as First, our XX progress. TELLOMAK lacutamab

We preliminary with reported due final year, this year. data have next data

Lymphoma Peripheral addition, Cell initial are year. T In data program our expected next

We next and natural platform generation presented end by conferences trial our Sanofi, in cancer the we of develop in lung partner pathway technology data platform that look plans we we forward encouraged ANKET our our continue where way this X to of believe very the including are represents engages. are a our continue evolution from adenosine monalizumab clinic the with parallel, at course. to In the year. advance to due with agents and sharing the we preclinical at the the Phase in NK cell For our results

we IPHXXXX year. to update track our Finally, IND look forward proprietary the be on to filed heard ANKET you've with further on as next

Let's slide. move to the now conclusion

all our Pharma you our net. meaningful And with can three and continue exciting to journey for throughout to at year-to-date in Lastly, the pillars. on made We future summary, look for and have business XX, as strategic patients positioned the build Slide we progress across our create Innate stakeholders. strategy value we tell,

on a managed our in continue with I invest carefully have progress our pleased second very into in we across we Collectively, and keeping continue And resources to driving innovative our to the deliver $XXX million This position are with am value concludes updated look XXXX. half our XX, a to that have business remarks. prepared patents. of We September We forward to strong so our medicine advancing can of as goal XXXX runway progress. ultimately pipeline. you cash to we our

the We will now open to questions. call

Please come go Nochomovitz from with of will first question Citigroup. ahead. the Our Yigal Instructions] [Operator line

Mondher Hi and tetra-specific team. one TELLOMAK on for one I ANKET. and two; just Thank then you taking the the question. much on very had

which is just the on non-expressor. interested the I the one I X, in Cohort with So TELLOMAK, was know

idea assuming of just what that TRs. validated the that's in You known so still there well are there opposed can is pick expressing had all obviously patients addition can known not curious another some CDXX variable good ANKET, target characterized still new very reason? is the tetra-specific target, a I'm well totally the as show of something as the because tetra-specific on beyond do above or some ANKET. a level and then to is the that KIRXDLX And so responses low you to them albeit those I introducing the very platform was tetra-specific to target

Thank there? thinking your on elaborate just could you you. if So

selection of not address then start this second I'm with activity have set it's the who the two question And not identification for absolutely Yigal of Cohort context nil, we'll you're about level target. over your with actually to you, zero. – and Thank going the will to hand Actually, – Yannis important and questions. one of it's we set-up seen very the Joyson correct we X, the

and We platform But have hypothesis ANKET CDXXst. have we some actually start the activities. that with the of to explain activity some and level let's

Yes. Hi speaking. Yigal, Yannis

Hi.

and by the as in action right. are the the to on the order selected well One think NKpXX XX, CDXX progressing molecule. activations the relying with variables tetra-specific of as I this molecule number cytokine mechanism We to new of you're clinic. in where really we relied same new – limit

to this these, look obviously expression and clinic, lot we a a the is the way that you stage with bringing after of into you them ideal the is to basically of the the clinic. line preclinical also still stable other in we're to decided advantage perspective well different one quite targets at validated validated which our as others meaning the That patients cause first opposed potential are So for proprietary and this time treatment, have the when go also at targets. as very CDXX of for be other expecting like have which the if from candidate lacutamab relapse target, target, program we

that have also address at activity responses least despite safety Yannis. that And have is I below to on antitumor expression you, level there have data too you really presented. we so We without the we model. on two asset your of tumor still much that published course have in generated Thank of the in May already adding the differentiated question the we various we profile as Cohort have but pre-clinical X based, ask short. Joyson X% in fact believe seen far, maybe to are why on

Yes.

mean, mentioned. the the just mycosis So you I reminder, Cohort a Cohort Xs as as in Yigal is mycosis X fungoides fungoides, expressing

of the number Now conditions. different there sort assay heterogeneity. assays is are course is One is Tumor the factors. of two

see So of levels even because activity non-expressors. of low those some two, in the we do

both also more assay exploring commerce looking all make further by at we're our cohort. this precise an to Now,

the So keep be does looking based will TELLOMAK we're at in cohort assay Cohort the mind also, have X a and X that FFPE in mind Cohort commerce were study a assay. [indiscernible] keeping which

some So the of we these low believe sort reasons that seeing you're level activity. are why

you. Thank it. Got

you. Thank

Graybosch Daina with SVB the go next of question ahead. line come will from Please Your Securities.

they a all guidelines, – project from blood of I or know, me if review? could us wonder wonder meet is, been that these FDA? guidelines Hi. if doses we've to dose can response Thank the if any I on the plan skin are as about in in for question you almost global about Two done don't what you approval, I whether And regulatory optimization randomized the you. you've TELLOMAK the used more response Thank talk hearing you you say accelerated whether or project OPTIMUS second are OPTIMUS, expectations rates lot lacutamab, loose two how question. to regulatory for focus for you not, let's then their remind if do the and but on rate and think diseases lacutamab. between

for Thank you, very question. Daina, important two

Joyson is the Sezary the about of course person the our think address, to our, right accelerated of evolution environment syndrome, and first Joyson? thinking probably in approval in of U.S. I all the lacutamab of the regulatory

So, sure.

So in benchmark regards may sort to of the the regulatory be discussions we're certainly. or looking regulators for, what ongoing them with in

for few in this approval the tougher in point a what So benchmark just is approval accelerated last approval, say to least the has accelerated they're I of so the scrutiny on as at time put course, program at months that's the because of bit been – at become considering we this, this for FDA. know want or this accelerated

is I think dose and in looked going justification project ensure number to justification. And forward is project continue to two OPTIMUS for justification dose have dose correctly regards OPTIMUS, interestingly is justified. the us just that dose we at

end we've been I with years several guided do you lacutamab that randomization done doses this significance. has must do the believe different FDA and, and I but they So the levels, has to on say don't doing different based development been it's for on statistical instead I drug that randomized think not a necessarily think it explore at for trial, accordingly.

Can a Can I up? have you follow us? remind

Daina, does that answer the question?

it sort at of because ago, explored us how happened many doses you remind doses? just patients you many Can various Yes. longer how and

did – hello? cut So doses. Did We different explore get off? intra just both we Hello. several I explored

I still hear. Joyson, can

I okay. Well, got don't off. cut okay, know if I

dosing different did dose explore So as both intra who well patients received single throughout. a as doses, patient several we

doses able and and PD? least patients adequate some doses of at So were do different look at we of PK to we have several the with number that

Thank you.

Phase in want know, that you ago, okay. have of you follow-up data we you where and couple published, maybe the years New detail you can if as England the send we escalation, a X Daina,

Yes, sorry, [indiscernible].

Thank Yes. you.

line with go Please Your next from question ahead. Swayampakula the HCW. will come Ramakanth of

Thank the the is Sezary syndrome from know trial you. – present RK that on you we final at work This data some of That to And what's little this drug, went about, you questions on HCW. quick you. same helpful. Thank ASH, the trial on PTCL? the expectation for be of itself? – Couple TELLOMAK but the the a for can bit would your TELLOMAK with results also the of highlight initial

you. We question. Hi. thank for RK, me thank let definitely the you

sure Let them just we them right. me to repeat got make

is So, regard words, profile? ash to have And to data with the on an expectation at for person be update questions. sort particular product address first Sezary the actually PTCL, presented about is of in of the in what one activity lacutamab second back and is we other level in again syndrome, you. and to once both Joyson the right targeted question the to Joyson,

mute, You're Joyson.

me sorry, Sezary ahead I didn't didn't question, go syndrome the let address I – question but and PTCL first. hear the

have reminder, of very global with who abstract from a a response of ORR was heavily was – syndrome, six monalizumab of median So that, pretreated a overall seen with this postpone in rate Sezary number were just global just ASH, for lines had as that published therapy. population to the a a XX.X%. we And did we of confirmed

do was that, the continue sorry, what see were very we encouraging that So we data we even the PTCL set encouraged question? and And final I'm to itself. would in data by expect

X, just sure so make the take to maybe got PTCL I try. will too I

the combination be group HEM cooperative call GEMOX. in we in the interim the activity chemotherapy, lacutamab lacutamab is and trials a have preliminary And around particular And known a XXXX; safety of Phase that we previous on have the Okay, trial PTCL, year. LYSA presented said the asking Xb trial. of European that as LYSA level we with combination so in an in is or well the for two with T-cell at monotherapy. you will of sponsored of that in an a testing and lymphoma, peripheral assessing were company data next update

Thanks taking Thank questions. for you. the

submitted No offline questions If go line. to I'll on the not, questions.

further phone time. No at this questions

Okay.

to a Smolentseva we question. Bryan Garnier. the Three So parts here question have from at Olga

expect could ESMO IPHXXXX for by And at from the for XX do give Phase of any you anti-CD from you an data any we across polls recent us favor Surface read X the Oncology? Firstly, should program see what IO? IPHXXXX

presentation say I ESMO at think await we the IO will it's to fair that details. further for

cell soon. provide and details know lung Phase are hope able As cancer, program we to to trial you starting very on X be this in further non-small

to are We unable they also allocation and are on comment prioritization. and companies, other

data So at that the we'll stick presented the end will to our program year. of the be and

you. Thank

Second How competitive do see bi-specifics? IPHXXXX question highly targeting the you of CDXX from into landscape fit Olga.

question. another Yes, important

I same the Yigal, think a believe, question line. asked I along

will We enter that are really update efficacy. filing an Yannis opportunity the, of a I fully provide as have differentiate the this on on IPHXX, molecule data as tetra-specific the next landscape course, the the completely say mitigate enter exact of was the competitive going validated so there into we here novel the is we also risk must is And ANKET after on target which safety, And tetra-specific. pursuing. evaluate selection far, aware first of both of but clinic. to way but improved that seen platform, to proprietary again we further this what an from here, the we are But in said year. landscape IND we'll indication technical is

well, and by So validated target. really that of the risk was our novel the choosing approach mitigate to platform established

patient you. last include as at pretreated lacutamab from we expect Should similar for update per final the the Olga. population Thank a And to highly syndrome data interim question Sézary ASH? in

and patients stating trial may but Again, therapy think, two prior of this be post-moga. I at lines needed Yes. least be have to in must I the obvious,

reason you different. when patient the being still the launching and some started and any line, of be no ended as may to As rest would we that late very reason the up was remember, think trial, trial in the the phase, moga of

abstract or criteria, of more median six criteria. a These prior main So we our according inclusion/exclusion systemic I IVB line at this And Final in presentation. efficacy top ASH prior by i.e. due fungoides syndrome therapy, we both cohort. forward despite further we are enroll line selection line having mogamulizumab. the are ASH are look systemic relapsed/refractory, our continue of and to earlier, and STAGE IVA the mycosis therapy, to two including to and of STAGE for data said the encouraged XXXX discussing data, Sezary as

Instructions] [Operator

you. Thank

more We on questions couple submitted online. a have

question at do for Chen for Submitted Evercore. Jingming to wait the What MF a SS to do decision? considerations combined? studying approval plan first before, So you file SS main a trial to matrix the or and in are

going terms I'm to agitation back handover of Yes, Joyson to in development MF. Joyson? recap Sézary our lacutamab in and strategy for

Mondher. Thanks,

mix. plan So That this the think our the first. answer course, in SS the That time, combined, partners to file file also do I we potential file we data, first number for open. your MF on a going keeping I for to approval is do options includes and in of includes even so are wait SS depend all the potential all lot think, question, considering during to to or SS studying both to for is trial one that to

So just making sure this Number data is and open the all are the drive what matrix considerations decision. for decision. main itself kind the our are one will options is, and of

a influence on the of the partner. major third strength then data is a evolve, look will two at for look we'll decision. as regulatory have And the Number landscape is, the starts is it sort our ability how we this. drive to to So, of

have submitted questions further online. you, I Joyson. Thank some

of lacutamab in consecutively at MF sets So confirming delivered Eric data two and Stifel. highly one, Berrigaud has Question SS.

the compound times deliver this on many the a past upon to promises? lacutamab speculative the quite data Now, think dependent at does not much and lacutamab the we the Therefore, good PTCL how other partner PTCL. explained the overall? is, of value on future the ability should in however, In of interim words, both dependent you PTCL how would stage. in heavily be future of if find of is This

the thing for first question. what Eric Thank we define right data the very science a I all, important and to follow would will do of based is course at we the you hand. of say, on

the You drug a are Sézary MF. this potential the completely in would having And hundred of the moving blockbuster business change maybe aware, is in there. well case from also of indication course, and million PTCL to PTCL clearly perspective just few in

validate ASH direction. point I is preliminary is need in time the through going trial into think to so abstract that at in the right data we to we the and signal the this far submitted have TELLOMAK

wait the think at I preliminary we to have least various I mind goal. for assess if the that next scenario. keep at shots, PTL year may in data we'll to emerge, say, data But two the

And the potential the asset. think to We opportunity of have identify of understand have value are I a generate are with the nevertheless, line, position how are risk, many set of of but opportunity it's which this second combination treat a to the option of patient activity difficult that high is maybe population. a in we data also agent in I but trial, monotherapy and an explored to to pretreated think, we single in group, to lacutamab trial in other disease. LYSA heavily explore another But thinking also And deliver this these which course, team. way actually being important by the we that only for not course, and are better there that the first frontline to

Thank you.

advanced Eric. lines patients be to TELLOMAK collected pre-treated on very treatments. with patients moga, are average Second from six with question you of required In previous

is less moga earlier and approved? therefore if treat would progresses used you it time now patients fair to that advanced say is As that

But the the moga said question. of couple the will to are phase as similar difficult launching important and launch months. an on to pre-treated in speculate I heavily still everywhere. next that be get not patient it's was it's think after recruited – what moga I reimbursed And in did Again, how earlier on even I'll I the said say

at region, when part up, ended access course, I in least say, of therapy. some in had the late major drug world, change very patient recruiting we to the wait didn't in, we with see And available. mogamulizumab of would clearly of So, in some we was the Europe. a line And

of and So think different, there six that of heavily up be with and trial line yes, would end rest reason any pretreated no the may we to of therapy. is the median

an no we design is: discussed I of think that TELLOMAK of exposed n That's, mathematically of we course, number in have be one. we the setting be is established meaningful have to of been two, And what by a) this when number with and, a activity mogamulizumab. validate of course, that. think, in post-moga data and patient generate there an the area course, would I of is the is important And importance who activity because will care. authority with health standard have

Eric. you. Considering first Thank a on of drug from fair treatment very question failed? existing previous comments to CDXX your in your antibodies would once go of CDXX to targets, it advanced the line have be expect stability Last

Yes, you, target question. stable line antigen is across the now but thank pretty antibodies, the including monoclonal indeed like Eric Yes, engagers. for of also different your mentioned, treatment, I your other CDXX T-cell

in of other You know are they but [indiscernible], targeting this CDXX. type NHL there are that also

one current very can of different X like we treatment engagers. mechanism what think a a you the Phase development is like saying in CAR as approved late NK but or the that we assumption stage monoclonal are pretty first T, start antibodies because are with fair also cell I that action So that are line of the mobilizing and treatment the advanced

Yannis. Thank you,

we online. think question more have I no

that you our strategic a seen like remarks continue would remind against as I to priority. you as have we execute So concluding maybe

We financial a position. strong have

into of well-funded XXXX. second are half the We

R&D with robust And our the while and monalizumab, As also our partnered that R&D to finally, these business which trial strategy a ANKET building wonderful our of move clinical with we Thank activity generation With much. R&D very proprietary and we highlighting next while stage to day. of course, platform, said, I with enforces a for in development you Wish cancer readouts lung program, look strength with continue reported, AstraZeneca our reads you. underway, long-term depth lacutamab early forward of core both sustainable the from further thank for near- and we'll further advance delivering set looking engine. early-stage portfolio our ahead, efforts. value, the clinic also out program in

today's gentlemen, thank conclude joining. all you that and We Ladies meeting. for will

disconnect. now may You